跳至主要内容
临床试验/NCT03019055
NCT03019055已完成1 期

Phase 1/1b Study of Redirected Autologous T Cells Engineered to Contain an Anti CD19 and Anti CD20 scFv Coupled to CD3ζ and 4-1BB Signaling Domains in Patients With Relapsed and/or Refractory CD19 or CD20 Positive B Cell Malignancies

Medical College of Wisconsin2 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2017年10月16日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
26
试验地点
2
主要终点
Number of Adverse Events After CAR 20/19-T Cell Infusion

研究概览

简要总结

This is a phase 1/1b, interventional single arm, open label, treatment study designed to evaluate the safety and feasibility of infusion of autologous T cells engineered to contain an anti-cluster of differentiation 19 (CD19) and anti-cluster of differentiation 20 (CD20) single chain variable fragment (scFv) coupled to cluster of differentiation CD3ζ (CD3ζ) and co-stimulatory domain 4-1BB (4-1BB) signaling domains in patients with relapsed and/or refractory CD19 or CD20 positive B cell malignancies

详细描述

This is a single center, single arm, open label phase I/1b study to demonstrate the feasibility of manufacturing CAR-T cells expressing tandem receptors against both CD20 and CD19 (CAR-20/19-T) in a completely closed system using the CliniMACS Prodigy device and then determine the safety of this dual targeted CAR in a first-in-human study of patients with relapsed and refractory B cell malignancies. Secondary outcomes will include response rates, and observed toxicities of the treatment, specifically the development of cytokine release syndrome (CRS), an inflammatory storm that has been seen with previous CAR-T therapies.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Sequential
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Number of Adverse Events After CAR 20/19-T Cell Infusion

时间窗: 28 days after infusion

This measure is the number of adverse events with grade 3 to 5 severity per Common Terminology Criteria for Adverse Events (ver. 4.03) occurring within the first 28 days following infusion.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Nirav Shah

Associate Professor

Medical College of Wisconsin

研究点 (2)

Loading locations...

相似试验

已完成
2 期
Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic LeukemiaPatients With B Cell ALL, Relapsed or Refractory, With no Available Curative Treatment Options
NCT02030847University of Pennsylvania42
已完成
1 期
CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to ChemotherapyHematopoietic/Lymphoid CancerAdult Acute Lymphoblastic Leukemia in RemissionB-cell Adult Acute Lymphoblastic LeukemiaB-cell Chronic Lymphocytic LeukemiaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRefractory Chronic Lymphocytic LeukemiaStage III Adult Diffuse Large Cell LymphomaStage III Chronic Lymphocytic LeukemiaStage III Grade 1 Follicular LymphomaStage III Grade 2 Follicular LymphomaStage III Grade 3 Follicular LymphomaStage III Mantle Cell LymphomaStage IV Adult Diffuse Large Cell LymphomaStage IV Chronic Lymphocytic LeukemiaStage IV Grade 1 Follicular LymphomaStage IV Grade 2 Follicular LymphomaStage IV Grade 3 Follicular LymphomaStage IV Mantle Cell LymphomaProlymphocytic Leukemia
NCT01029366University of Pennsylvania26
Unknown
不适用
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant TumorsB Cell LymphomaB Cell LeukemiaMyelomaPancreatic CarcinomaAdenocarcinoma of Esophagogastric JunctionHepatocellular Carcinoma
NCT03302403Kang YU18
Unknown
1 期
Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple MyelomaRefractory or Relapsed Multiple Myeloma
NCT03716856First Affiliated Hospital of Zhejiang University11
Unknown
不适用
Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple MyelomaRefractory or Relapsed Multiple Myeloma
NCT03380039Xinhua Hospital, Shanghai Jiao Tong University School of Medicine6